BridgeBio reported positive top-line results from its global phase III Propel 3 trial of oral infigratinib in children with achondroplasia, meeting growth and body-composition endpoints. The drug, an FGFR3 inhibitor, produced growth outcomes that matched the marketed therapy Voxzogo and offers an oral alternative to existing injectable options. BridgeBio plans regulatory submissions later this year and positions infigratinib as a differentiated, oral FGFR3-targeting therapy. The readout adds competitive pressure in the achondroplasia market and could influence payer and prescriber choices where route of administration matters for pediatric adherence and long-term management.